Can methotrexate be used to treat psoriasis in a patient with metabolic-associated fatty liver disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Methotrexate Can Be Used for Psoriasis in Patients with MAFLD, But Requires Enhanced Monitoring

Methotrexate is not contraindicated in patients with MAFLD (metabolic-associated fatty liver disease) and can be used to treat psoriasis, but these patients require baseline liver fibrosis assessment and annual monitoring due to their elevated baseline risk of hepatotoxicity. 1

Key Clinical Approach

Risk Stratification

Patients with MAFLD fall into the high-risk category for methotrexate-induced hepatotoxicity. The 2020 AAD-NPF guidelines explicitly identify obesity, diabetes, and hyperlipidemia—the core components of metabolic syndrome underlying MAFLD—as risk factors that increase susceptibility to methotrexate liver injury 1. Importantly, nonalcoholic steatohepatitis (the inflammatory form of MAFLD) is a common psoriasis comorbidity that can be aggravated by methotrexate 1.

Pre-Treatment Requirements

Before initiating methotrexate in a patient with MAFLD:

  • Perform noninvasive liver fibrosis assessment using vibration-controlled transient elastography (TE) or refer to GI/hepatology 1
  • Baseline liver biopsy is NOT recommended, regardless of risk factors 1
  • Methotrexate can only be started if cirrhosis risk is low based on imaging results 1
  • Check baseline liver function tests, CBC, and renal function 1

Ongoing Monitoring Protocol

For patients with MAFLD on methotrexate:

  • Annual GI/hepatology referral or transient elastography (or both) 1
  • Liver function tests every 3-6 months (assuming no abnormalities) 1
  • If persistent LFT elevations occur, repeat in 2-4 weeks; if still abnormal, refer to GI 1
  • Monitor CBC every 3-6 months for myelosuppression 1

Evidence Reconciliation: The Methotrexate Controversy

There is an important divergence between guideline recommendations and emerging research evidence:

Guideline Position (Conservative)

The AAD-NPF guidelines 1 maintain that MAFLD increases hepatotoxicity risk and recommend enhanced monitoring, reflecting traditional concerns about methotrexate liver injury.

Recent Research Evidence (Reassuring)

Multiple high-quality studies from 2022-2024 challenge the traditional view:

  • A 2024 UK study of 204 psoriasis patients found no association between cumulative methotrexate dose and liver fibrosis (P=0.626), while BMI, metabolic syndrome, and diabetes were the actual risk factors 2
  • A 2024 Turkish study confirmed psoriasis patients have elevated baseline liver fibrosis risk, but long-term methotrexate use had no adverse effect on APRI or FIB-4 scores 3
  • A 2023 UK cohort of 999 patients concluded that the risk of liver fibrosis from methotrexate has been overestimated, with diabetes (OR 3.19) being the most significant risk factor, not methotrexate exposure 4
  • A 2022 meta-analysis found no statistically significant association between methotrexate dose and liver fibrosis, attributing injury to metabolic liver disease rather than methotrexate itself 5

Clinical Implication

The liver injury risk in MAFLD patients is primarily driven by their underlying metabolic disease, not methotrexate per se. However, until guidelines are updated, follow the conservative AAD-NPF monitoring protocol while recognizing that methotrexate itself may not be the culprit.

Practical Algorithm

  1. Confirm MAFLD diagnosis and assess severity
  2. Exclude absolute contraindications: chronic liver disease (hepatitis B/C), alcoholic liver disease, pre-existing cirrhosis 6
  3. Obtain baseline transient elastography:
    • If LSM <7.5 kPa: Proceed with methotrexate, repeat TE annually
    • If LSM 7.5-9.5 kPa: Proceed with caution, repeat TE annually, consider GI referral
    • If LSM >9.5 kPa: Consider liver biopsy or alternative therapy 7
  4. Start methotrexate at 7.5-15 mg weekly with folic acid supplementation 1
  5. Monitor LFTs every 3-6 months; if persistently elevated, refer to GI 1
  6. Focus on metabolic optimization: Weight loss, diabetes control, and lipid management are more important than methotrexate avoidance 2, 4

Critical Caveats

  • MAFLD is NOT a contraindication to methotrexate; alcoholic liver disease and chronic hepatitis ARE contraindications 6
  • Female sex and metabolic syndrome confer higher fibrosis risk than methotrexate exposure itself 8
  • Transient elastography is superior to FIB-4 or APRI for detecting fibrosis in this population 2, 8
  • Consider biologics (e.g., secukinumab) if patient has advanced fibrosis or multiple metabolic risk factors, as they have neutral hepatic effects 9

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.